Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates World First Multiple Mechanisms of Action against E. coli bacteria

NASDAQ Market News

NEXT STORY
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
PREV STORY
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency

author_avatar
NASDAQ Market News

Orion acquires sales and distribution rights for certain European Countries for Parkinson’s disease drug Stalevo

ORION CORPORATION              PRESS RELEASE           4 DECEMBER  2018 at 15.00 EET Orion acquires sales ...

author_avatar
NASDAQ Market News

Sequana Medical Announces 2019 Full Year Results and 2020 Outlook

author_avatar
NASDAQ Market News